Lurbinectedin对比聚乙二醇脂质体阿霉素或拓扑替康治疗铂耐药卵巢癌:CORAIL随机III期研究
CORAIL是一项多中心、随机、对照、开放标签III期研究,共纳入442例铂耐药卵巢癌患者,按1:1随机分配至Lurbinectedin组或对照组(PLD或拓扑替康)。主要终点独立评审委员会评估的PFS未达到:Lurbinectedin组中位PFS为3.5个月,对照组为3.6个月(分层log-rank P=0.6294;HR=1.057)。Lurbinectedin组≥3级治疗相关不良事件发生率为47.9%,低于对照组的64.8%(P=0.0005)。
要点
- Lurbinectedin未改善铂耐药卵巢癌患者的PFS,两组中位PFS分别为3.5和3.6个月。
- Lurbinectedin组≥3级治疗相关不良事件发生率为47.9%,显著低于对照组的64.8%。
- Lurbinectedin耐受性更好,但抗肿瘤疗效与现行标准治疗相似。
核心结论
- 主要终点PFS改善未达到,Lurbinectedin在铂耐药卵巢癌中显示出与标准治疗相似的抗肿瘤疗效且耐受性更好。
研究设计与样本
- 多中心、随机、对照、开放标签III期试验(CORAIL),442例铂耐药卵巢癌患者按1:1随机分配至Lurbinectedin组(221例)或对照组(221例,其中PLD 127例、拓扑替康94例)。
- 分层因素为PS评分(0 vs ≥1)、既往PFI(1-3个月 vs >3个月)和既往化疗线数(1-2 vs 3)。
- 主要终点为独立评审委员会评估的全部随机患者的PFS。
主要发现
- 中位随访25.6个月,Lurbinectedin组中位PFS为3.5个月(95%CI 2.1-3.7),对照组为3.6个月(95%CI 2.7-3.8),分层log-rank P=0.6294,HR=1.057。
- ≥3级治疗相关不良事件发生率:Lurbinectedin组47.9%,对照组64.8%(P=0.0005),主要归因于血液学毒性。
- Lurbinectedin组最常见的≥3级不良事件为乏力(7.3%)和恶心(5.9%);对照组为黏膜炎(8.5%)和乏力(8.0%)。
关键数值与推荐
- Lurbinectedin给药方案:3.2 mg/m2,1小时静脉输注,每3周一次。
- 对照方案:PLD 50 mg/m2,1小时静脉输注,每4周一次;或拓扑替康1.50 mg/m2,30分钟静脉输注,第1-5天,每3周一次。
临床怎么用
- 对于铂耐药卵巢癌,Lurbinectedin未显示PFS优势,但可作为耐受性更好的替代选择,尤其适用于无法耐受标准治疗毒性的患者。
- 临床决策时需权衡疗效与毒性,Lurbinectedin的血液学毒性较低,但乏力等不良事件仍需关注。
局限性
- 开放标签设计可能引入偏倚。
- 对照组包含两种不同治疗方案(PLD和拓扑替康),可能影响结果解释。
- 中位随访25.6个月,总生存数据尚未成熟。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The randomized phase 3 CORAIL trial evaluated whether lurbinectedin improved progression-free survival (PFS) compared to pegylated liposomal doxorubicin (PLD) or topotecan in patients with platinum-resistant ovarian cancer. METHODS: Patients were randomly assigned (1:1) to lurbinectedin 3.2 mg/m2 1-h i.v. infusion q3wk (experimental arm), versus PLD 50 mg/m2 1-h i.v. infusion q4wk or topotecan 1.50 mg/m2 30-min i.v. infusion Days 1-5 q3wk (control arm). Stratification factors were PS (0 vs. ≥1), prior PFI (1-3 months vs. >3 months), and prior chemotherapy lines (1-2 vs. 3). The primary endpoint was PFS by Independent Review Committee in all randomized patients. This study was registered with ClinicalTrials.gov, NCT02421588. RESULTS: 442 patients were randomized: 221 in lurbinectedin arm and 221 in control arm (127 PLD and 94 topotecan). With a median follow-up of 25.6 months, median PFS was 3.5 months (95% CI, 2.1-3.7) in the lurbinectedin arm and 3.6 months (95% CI, 2.7-3.8) in the control arm (stratified log-rank p = 0.6294; HR = 1.057). Grade ≥ 3 treatment-related adverse events (AEs) were most frequent in the control arm: 64.8% vs. 47.9% (p = 0.0005), mainly due to hematological toxicities. The most common grade ≥ 3 AEs were: fatigue (7.3% of patients) and nausea (5.9%) with lurbinectedin; mucosal inflammation (8.5%) and fatigue (8.0%) in the control arm. CONCLUSIONS: The primary endpoint of improvement in PFS was not met. Lurbinectedin showed similar antitumor efficacy and was better tolerated than current standard of care in patients with platinum-resistant ovarian cancer.
引用
- Gaillard S, Oaknin A, Ray-Coquard I, et al. Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL). Gynecol Oncol. 2021. PMID: 34521554. doi:10.1016/j.ygyno.2021.08.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。